Literature DB >> 29775417

Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis.

Xiaoxu Zhou1,2, Chongxiang Xiong1, Evelyn Tolbert1, Ting C Zhao3, George Bayliss1, Shougang Zhuang1,4.   

Abstract

Enhancer of zeste homolog-2 (EZH2) is a methyltransferase that induces histone H3 lysine 27 trimethylation (H3K27me3) and functions as an oncogenic factor in many cancer types. Its role in renal epithelial-mesenchymal transition (EMT) remains unknown. In this study, we found that EZH2 and H3K27me3 were highly expressed in mouse kidney with unilateral ureteral obstruction and cultured mouse kidney proximal tubular (TKPT) cells undergoing EMT. Inhibition of EZH2 with 3-deazaneplanocin A (3-DZNeP) attenuated renal fibrosis, which was associated with preserving E-cadherin expression and inhibiting Vimentin up-regulation in the obstructed kidney. Treatment with 3-DZNeP or transfection of EZH2 siRNA also inhibited TGF-β1-induced EMT of TKPT cells. Injury to the kidney or cultured TKPT cells resulted in up-regulation of Snail-l family transcriptional repressor (Snail)-1 and Twist family basic helix-loop-helix (BHLH) transcription factor (Twist)-1, which are 2 transcription factors, and down-regulation of phosphatase and tensin homolog, a protein tyrosine phosphatase associated with inhibition of PI3K-protein kinase B (AKT) signaling; EZH2 inhibition or silencing reversed all those responses. 3-DZNeP was also effective in suppressing epithelial arrest at the G2/M phase and dephosphorylating AKT and β-catenin in vivo and in vitro. These data indicate that EZH2 activation contributes to renal EMT and fibrosis through activation of multiple signaling pathways and suggest that EZH2 has potential as a therapeutic target for treatment of renal fibrosis.-Zhou, X., Xiong, C., Tolbert, E., Zhao, T. C., Bayliss, G., Zhuang, S. Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis.

Entities:  

Keywords:  AKT; EMT; PTEN; Snail; Twist

Year:  2018        PMID: 29775417      PMCID: PMC6181636          DOI: 10.1096/fj.201800237R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  59 in total

1.  Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions.

Authors:  Hector Peinado; Miguel Quintanilla; Amparo Cano
Journal:  J Biol Chem       Date:  2003-03-28       Impact factor: 5.157

Review 2.  The role of EMT in renal fibrosis.

Authors:  Rosemarie M Carew; Bo Wang; Phillip Kantharidis
Journal:  Cell Tissue Res       Date:  2011-08-16       Impact factor: 5.249

Review 3.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

4.  Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Authors:  Nina Wagener; Stephan Macher-Goeppinger; Maria Pritsch; Johannes Hüsing; Karin Hoppe-Seyler; Peter Schirmacher; Jesco Pfitzenmaier; Axel Haferkamp; Felix Hoppe-Seyler; Markus Hohenfellner
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

5.  Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis.

Authors:  Marlene Krämer; Clara Dees; Jingang Huang; Inga Schlottmann; Katrin Palumbo-Zerr; Pawel Zerr; Kolja Gelse; Christian Beyer; Alfiya Distler; Victor E Marquez; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Ann Rheum Dis       Date:  2012-08-21       Impact factor: 19.103

6.  Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD.

Authors:  Ruben Poesen; Liesbeth Viaene; Kristin Verbeke; Kathleen Claes; Bert Bammens; Ben Sprangers; Maarten Naesens; Yves Vanrenterghem; Dirk Kuypers; Pieter Evenepoel; Björn Meijers
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

7.  Origin and function of myofibroblasts in kidney fibrosis.

Authors:  Valerie S LeBleu; Gangadhar Taduri; Joyce O'Connell; Yingqi Teng; Vesselina G Cooke; Craig Woda; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Med       Date:  2013-06-30       Impact factor: 53.440

8.  Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease.

Authors:  M Teresa Grande; Berta Sánchez-Laorden; Cristina López-Blau; Cristina A De Frutos; Agnès Boutet; Miguel Arévalo; R Grant Rowe; Stephen J Weiss; José M López-Novoa; M Angela Nieto
Journal:  Nat Med       Date:  2015-08-03       Impact factor: 53.440

Review 9.  Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications.

Authors:  Silvia Juliana Serrano-Gomez; Mazvita Maziveyi; Suresh K Alahari
Journal:  Mol Cancer       Date:  2016-02-24       Impact factor: 27.401

10.  Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells.

Authors:  Kyoung-Ok Hong; Ji-Hong Kim; Ji-Soo Hong; Hye-Jung Yoon; Jae-Il Lee; Sam-Pyo Hong; Seong-Doo Hong
Journal:  J Exp Clin Cancer Res       Date:  2009-02-26
View more
  15 in total

Review 1.  Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

Review 2.  Epigenetics in kidney diseases.

Authors:  Hao Ding; Lu Zhang; Qian Yang; Xiaoqin Zhang; Xiaogang Li
Journal:  Adv Clin Chem       Date:  2020-10-21       Impact factor: 6.303

3.  Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway.

Authors:  Li Wen; Shao-Hua Tao; Fan Guo; Ling-Zhi Li; Hong-Liu Yang; Yan Liang; Li-Dan Zhang; Liang Ma; Ping Fu
Journal:  Acta Pharmacol Sin       Date:  2021-12-22       Impact factor: 7.169

4.  FOXM1 drives proximal tubule proliferation during repair from acute ischemic kidney injury.

Authors:  Monica Chang-Panesso; Farid F Kadyrov; Matthew Lalli; Haojia Wu; Shiyo Ikeda; Eirini Kefaloyianni; Mai M Abdelmageed; Andreas Herrlich; Akio Kobayashi; Benjamin D Humphreys
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

5.  Targeting lysine-specific demethylase 1A inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis.

Authors:  Xiaoqin Zhang; Linda Xiaoyan Li; Chen Yu; Karl A Nath; Shougang Zhuang; Xiaogang Li
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

6.  Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.

Authors:  Yan Jiang; Chan Xiang; Fan Zhong; Yang Zhang; Liyan Wang; Yuanyuan Zhao; Jiucun Wang; Chen Ding; Li Jin; Fuchu He; Haijian Wang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

7.  Histone demethylase JMJD3 protects against renal fibrosis by suppressing TGFβ and Notch signaling and preserving PTEN expression.

Authors:  Chao Yu; Chongxiang Xiong; Jinhua Tang; Xiying Hou; Na Liu; George Bayliss; Shougang Zhuang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

8.  Lead exposure induces dysregulation of constitutive heterochromatin hallmarks in live cells.

Authors:  Oscar F Sánchez; Li F Lin; Junkai Xie; Jennifer L Freeman; Chongli Yuan
Journal:  Curr Res Toxicol       Date:  2021-12-11

9.  miR‑101a‑3p overexpression prevents acetylcholine‑CaCl2‑induced atrial fibrillation in rats via reduction of atrial tissue fibrosis, involving inhibition of EZH2.

Authors:  Jing Zhu; Ning Zhu; Jian Xu
Journal:  Mol Med Rep       Date:  2021-08-26       Impact factor: 2.952

Review 10.  Histone Methyltransferases as Therapeutic Targets for Kidney Diseases.

Authors:  Chao Yu; Shougang Zhuang
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.